HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
Earnings Winners: BHP, NAB & TLS lead the pack
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,302.00 | 8.10 | 0.09% |
| CAC 40 | 8,398.78 | 30.25 | -0.36% |
| DAX 40 | 25,043.57 | 234.64 | -0.93% |
| Dow JONES (US) | 49,395.16 | 267.50 | -0.54% |
| FTSE 100 | 10,627.04 | 59.14 | -0.55% |
| HKSE | 26,657.84 | 48.10 | -0.18% |
| NASDAQ | 22,682.73 | 70.91 | -0.31% |
| Nikkei 225 | 56,833.29 | 634.54 | -1.10% |
| NZX 50 Index | 13,310.31 | 133.89 | -1.00% |
| S&P 500 | 6,861.89 | 19.42 | -0.28% |
| S&P/ASX 200 | 9,076.30 | 11.90 | 0.13% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |